

23 October 2013

Updated market information: RFP - Supply of somatropin

On the 8^h of October 2013, PHARMAC released a request for proposal for supply of somatropin in New Zealand, PHARMAC has received requests from two potential suppliers for more information regarding the use of somatropin in the community.

The information in the table below relates to the estimated subsidised market size of somatropin in the community. The information is approximate and indicative only. PHARMAC makes no representation as to the accuracy of this information or as to the level of sales or likely sales of somatropin and, while PHARMAC has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information. PHARMAC is not obliged to notify you in the event of any change to the figures below.

Funded somatropin dispensed (mg) by cartridge type, in the community, for the 2009/10 – 2012/13 financial years (1 July – 30 June):

Chemical and presentation	Funded somatropin dispensing (mg)			
	Year ending 30 June 2010	Year ending 30 June 2011	Year ending 30 June 2012	Year ending 30 June 2013
Somatropin inj cartridge 16 iu (5.3 mg)	2,502 mg	6,360 mg	16,308 mg	18,577 mg
Somatropin inj cartridge 36 iu (12 mg)	57,036 mg	72,792 mg	91,140 mg	81,804 mg
Total mg dispensed (approx)	59,538 mg	79,152 mg	107,448 mg	100,381 mg

The number of patients and the average daily dose for adults and children as at 10 October 2013 is shown below:

	Adults (ages 18 and above)	Children (ages 0 – 18)
Number of patients	170 patients	242 patients
Average daily dose	0.3517 mg	1.0859 mg
Total average daily dose	59.8 mg	262.8 mg